AFT Pharmaceuticals Limited (NZE:AFT)

Market Cap	270.55M
Revenue (ttm)	198.51M
Net Income (ttm)	11.61M
Shares Out	104.87M
EPS (ttm)	0.10
PE Ratio	25.37
Forward PE	17.83
Dividend	0.02 (0.62%)
Ex-Dividend Date	Jun 19, 2024

Volume	5,317
Average Volume	35,933
Open	2.550
Previous Close	2.580
Day's Range	2.550 - 2.620
52-Week Range	2.370 - 3.420
Beta	0.42
RSI	47.90
Earnings Date	May 22, 2025

About AFT Pharmaceuticals

AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, gastrointestinal, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, vitamins, and supplements, as well as other products. The company has collaboration with Belgium’s Hyloris Pharmaceuticals to develop a novel innovative injectable iron deficiency therapy. AFT Pharma...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 110
• Stock Exchange: New Zealand Stock Exchange
• Ticker Symbol: AFT

Financial Performance

In 2023, AFT Pharmaceuticals's revenue was 195.41 million, an increase of 24.75% compared to the previous year's 156.64 million. Earnings were 15.61 million, an increase of 46.51%.